These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 3317357

  • 1. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine.
    André FE, Safary A.
    Postgrad Med J; 1987; 63 Suppl 2():169-77. PubMed ID: 3317357
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
    Crovari P, Crovari PC, Petrilli RC, Icardi GC, Bonanni P.
    Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
    [Abstract] [Full Text] [Related]

  • 3. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
    Just M, Berger R, Just V.
    Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
    Bergamini F, Zanetti A.
    Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients.
    Bruguera M, Cremades M, Mayor A, Sánchez Tapias JM, Rodés J.
    Postgrad Med J; 1987; 63 Suppl 2():155-8. PubMed ID: 3317354
    [Abstract] [Full Text] [Related]

  • 6. Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males.
    Laukamm-Josten U, von Laer G, Feldmeier H, Bienzle U, Uy A, Thomssen R, Guggenmoos-Holzmann I.
    Postgrad Med J; 1987; 63 Suppl 2():143-6. PubMed ID: 3317351
    [Abstract] [Full Text] [Related]

  • 7. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers.
    Goudeau A, Denis F, Mounier M, Dubois F, Klein J, Godefroy A, Ballet M, Mountij A.
    Postgrad Med J; 1987; 63 Suppl 2():125-8. PubMed ID: 3317347
    [Abstract] [Full Text] [Related]

  • 8. Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults.
    Scheiermann N, Gesemann KM, Kreuzfelder E, Paar D.
    Postgrad Med J; 1987; 63 Suppl 2():115-9. PubMed ID: 3317345
    [Abstract] [Full Text] [Related]

  • 9. Clinical development of a new recombinant DNA hepatitis B vaccine.
    Safary A, André F.
    Postgrad Med J; 1987; 63 Suppl 2():105-7. PubMed ID: 3317343
    [Abstract] [Full Text] [Related]

  • 10. Reactogenicity and immunogenicity of different lots of a yeast-derived hepatitis B vaccine.
    Wiedermann G, Ambrosch F, Kremsner P, Kunz C, Hauser P, Simoen E, André F, Safary A.
    Postgrad Med J; 1987; 63 Suppl 2():109-13. PubMed ID: 3317344
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates.
    Meheus A, Alisjahbana A, Vranckx R, Sukadi A, Usman A, Ngantung W, Sugita E, Safary A, André F, Reniers J.
    Postgrad Med J; 1987; 63 Suppl 2():139-41. PubMed ID: 3317350
    [Abstract] [Full Text] [Related]

  • 12. Yeast-derived hepatitis B vaccine in thalassaemic patients: a preliminary report.
    Giammanco G, De Grandi V, Pignato S, Dolci C, Congia M, Pisu C, De Virgiliis S.
    Postgrad Med J; 1987; 63 Suppl 2():151-4. PubMed ID: 3317353
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and tolerance of a yeast-derived hepatitis B vaccine in homosexual men.
    Prinsen H, Goilav C, Safary A, André FE, Piot P.
    Postgrad Med J; 1987; 63 Suppl 2():147-9. PubMed ID: 3317352
    [Abstract] [Full Text] [Related]

  • 14. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects.
    Ambrosch F, Frisch-Niggemeyer W, Kremsner P, Kunz C, André F, Safary A, Wiedermann G.
    Postgrad Med J; 1987; 63 Suppl 2():129-35. PubMed ID: 3317348
    [Abstract] [Full Text] [Related]

  • 15. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen.
    Schellekens H, de Reus A, Peetermans JH, van Eerd PA.
    Postgrad Med J; 1987; 63 Suppl 2():93-6. PubMed ID: 3317363
    [Abstract] [Full Text] [Related]

  • 16. Vaccination of newborns of HBsAg-positive carrier mothers with a recombinant DNA hepatitis B vaccine.
    Cadranel S, Zeghlache S, Fernandez S, Safary A, André F.
    Postgrad Med J; 1987; 63 Suppl 2(736):159-60. PubMed ID: 3317355
    [Abstract] [Full Text] [Related]

  • 17. Immunological properties of recombinant HBsAg produced in yeast.
    Hauser P, Voet P, Simoen E, Thomas HC, Pêtre J, De Wilde M, Stephenne J.
    Postgrad Med J; 1987; 63 Suppl 2():83-91. PubMed ID: 2446304
    [Abstract] [Full Text] [Related]

  • 18. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children.
    Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL.
    Hepatology; 1999 Mar; 29(3):924-7. PubMed ID: 10051499
    [Abstract] [Full Text] [Related]

  • 19. Clinical experience with a recombinant DNA hepatitis B vaccine.
    Andre FE.
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):501-10. PubMed ID: 2464196
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V, Nandakumar S, Shanmugam S, Shankar EM, Thangavel S, Kulkarni PS, Thyagarajan SP.
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.